Thomas J. Meloro is Chair of the Intellectual Property Department and a partner in the firm's Litigation Department. Tom focuses on litigation and adversarial matters concerning patents, trademarks, and trade secrets. His litigation experience has spanned across technologies and industries ranging from pharmaceuticals to telecommunications, with particular emphasis on pharmaceutical and biologic products, medical products, and consumer products. Tom was recognized by Best Lawyers in America (2015) for his work in the area of Patent Litigation.
Tom's work includes counseling on patent validity, enforceability and infringement, as well as intellectual property issues associated with licensing, mergers and other transactions. Tom represents early-stage entities, small and large cap companies, academic institutions, private equity investors and others in such matters.
In his practice at Willkie and previously, Tom has represented a variety of major life sciences and technology companies in litigation matters. In the pharmaceutical field, Tom has been lead counsel in litigations involving drug products including: paricalcitol (Zemplar), dexmedetomidine (Precedex), diclofenac (Cambia), clindamycin/benzoyl peroxide (Acanya), lansoprazole (Prevacid Solutabs), cefdinir (Omnicef), minocycline (Solodyn), mixed amphetamines (Adderall XR), amlodipine besylate (Norvasc), and amoxiclav (Augmentin).
Tom also has significant experience with biologic products, including several trials concerning patents related to recombinant human growth hormone. His clients prevailed after trial and were awarded a judgment that the patent on biosynthetic ripe human growth hormone was invalid and unenforceable for inequitable conduct.